Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke "ESS"

Completed

Phase 2/3 Results

Summary of Purpose

The purpose of this randomized, double-blind, placebo-controlled multicenter study is to determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral artery territory, the effect of a three-day high-dose, intravenous erythropoietin treatment on functional outcome up to a follow-up of 90 days.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 21 October 2008.

1 Jan 2003 17 Jan 2008 1 Jun 2008 1 Jun 2008 1 Sep 2008 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Dr. Claudia Bartels (PhD) Division of Clinical Neuroscience Max Planck Institute of Experimental Medicine Hermann-Rein-Str. 3 D-37075 Göttingen, Germany Tel: 49-551-3899626 Fax: 49-551-3899670

    ehrenreich@em.mpg.de